Global Human Microbiome Market Size, Share, and COVID-19 Impact Analysis, By Product (Drugs, Probiotics, Prebiotics, and Synbiotics), By Disease (Infectious, Gastrointestinal, and Endocrine & Metabolic), By Type (BCT/FMT and Live Biotherapeutics), By End User (Hospitals & Clinics and Long-term Care), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Human Microbiome Market Insights Forecasts to 2035

• The Global Human Microbiome Market Size Was Estimated at USD 0.79 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 31.42% from 2025 to 2035
• The Worldwide Human Microbiome Market Size is Expected to Reach USD 15.95 Billion by 2035
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Human Microbiome Market size was worth around USD 0.79 billion in 2024 and is predicted to grow to around USD 15.95 billion by 2035 with a compound annual growth rate (CAGR) of 31.42% from 2025 and 2035. The increasing significance of the microbiome’s role in health and disease, advancements in microbiome analysis technologies, and the increased demand for personalized medicine are primarily responsible for driving the human microbiome market globally.

Market Overview

The human microbiome market refers to the market emphasizing the understanding and application of microbial communities living on and within the human body. Human microbiome is the aggregate of all microbiota that reside on or within human tissues and biofluids, along with the corresponding anatomical sites in which they reside, including the GI tract, skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, and the biliary tract. The increasing significance of human microbiome in health and diseases, as well as the upsurging trend of personalized medicine, are significantly driving the human microbiome market.   

Revolutionization of microbiome-based therapies by the use of AI-driven technologies, which enables personalized healthcare, is providing growth opportunities in the human microbiome market.

Report Coverage

This research report categorizes the human microbiome market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the human microbiome market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the human microbiome market.

Driving Factors

The increasing significance of the microbiome’s role in health and disease, including digestion, immune function, and nutrient absorption, is driving the market for human microbiome. Further, the surging trend of personalized medicine is driving the market demand for human microbiomes for tailoring interventions for better disease management and improved patient outcomes. In addition, the advancement in microbiome analysis technologies that allow researchers to identify and quantify the microbial species leads to the market growth. Collaborative efforts between microbiome industries and organizations, along with the growing number of startups and SMEs, are significantly contributing to driving the market growth for the human microbiome.  

Restraining Factors

Complex regulatory policies and increased investment required for the commercialization of human microbiome products are challenging the market growth, as these factors may slow the patient adoption rate and complexity in the development of human microbiome-based therapy. Further, the reduced adoption of microbiome-based therapies owing to the lack of awareness and education among patients and healthcare providers may hamper the market.

Market Segmentation

The human microbiome market share is classified into product, disease, type, and end user.

• The probiotics segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product, the human microbiome market is divided into drugs, probiotics, prebiotics, and synbiotics. Among these, the probiotics segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period. An increasing consumption of probiotic-rich foods, beverages, and supplements as a natural and effective way of enhancing health by consumers is driving the market in the probiotics segment.

• The gastrointestinal segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the disease, the human microbiome market is divided into infectious, gastrointestinal, and endocrine & metabolic. Among these, the gastrointestinal segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Gastrointestinal conditions include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). An increasing demand for personalized therapies, along with rising regulatory approvals and clinical pipelines, is driving the market.

• The live biotherapeutics segment dominated the human microbiome market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the type, the human microbiome market is divided into BCT/FMT and live biotherapeutics. Among these, the live biotherapeutics segment dominated the human microbiome market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Live biotherapeutics involve the use of the microbiome’s potential for treating or preventing various conditions, including chronic diseases like gastrointestinal disorders and metabolic conditions.

• The hospitals & clinics segment dominated the market with the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the human microbiome market is divided into hospitals & clinics and long-term care. Among these, the hospitals & clinics segment dominated the market with the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. An increasing use of human microbiome in the prevention and treatment of infections by studying and developing new therapies escalates the market growth in the hospitals & clinics segment.

Regional Segment Analysis of the Human Microbiome Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the human microbiome market over the predicted timeframe.

North America is anticipated to hold the largest share of the human microbiome market over the predicted timeframe. The presence of well-established research infrastructure, as well as a robust biotechnology and healthcare industry, is significantly contributing to driving the regional market for human microbiome. An increasing product demand, including probiotics and prebiotics, owing to the prevalence of lifestyle diseases contributing to propel the market demand.

Asia Pacific is expected to grow at a rapid CAGR in the human microbiome market during the forecast period.  Awareness about microbiome health, emerging healthcare and biotechnology industries, and the government's increasing support for personalized medicine are significantly contributing to propelling the human microbiome market. Further, advancements in microbiome sequencing technology are contributing to driving the market growth for the human microbiome.

Europe is expected to hold a significant market share of the human microbiome market during the projected timeframe. An increasing prevalence of lifestyle and chronic diseases, as well as the development of human microbiome therapeutics for disease treatment significantly driving the regional market growth. The presence of major players, including Nestle, Ferring Pharmaceuticals, Resbiotics, is driving the market growth in the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the human microbiome market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Seres Therapeutics
• BiomeBank
• BioHM Health Inc.
• Optibiotix Health plc.
• Infinant Health Inc.
• Exegi Pharma LLC
• Ferring Pharmaceuticals
• Seed Health, Inc.
• Pendulum
• Actial Farmaceutica SRL
• Resbiotic
• Biogaia AB
• Vedanta Biosciences Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In December 2024, GluCare.Health collaborated with Pendulum Therapeutics to evaluate the impact of novel next-generation probiotics on Metabolic Health. This collaboration aims to assess the effectiveness of the Pendulum Glucose Control probiotic on glycemic control, weight management, food cravings, and overall metabolic health, conducted under GluCare.Health’s unique hybrid model of care.
• In August 2024, Pendulum Therapeutics, in collaboration with BiomeSense announced the launch of an innovative new pilot study entitled “Detection of Akkermansia muciniphila Utilizing Serial Longitudinal Samples with the BiomeSense GutLab: An Open-Label Proof of Concept Study.” Their groundbreaking research aims to advance the scientific understanding of the human microbiome by focusing on continuous detection of Akkermansia muciniphila, a keystone strain in the gut microbiome, using a new data generation technology.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the human microbiome market based on the below-mentioned segments: 

Global Human Microbiome Market, By Product

• Drugs
• Probiotics
• Prebiotics
• Synbiotics

Global Human Microbiome Market, By Disease

• Infectious
• Gastrointestinal
• Endocrine & Metabolic

Global Human Microbiome Market, By Type

• BCT/FMT
• Live Biotherapeutics

Global Human Microbiome Market, By End User

• Hospitals & Clinics
• Long-term Care

Global Human Microbiome Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa